Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

被引：43

作者：

Peng, AW

Milleri, S

Stein, DS

机构：

[1] Glaxo Wellcome Inc, Dept Clin Pharmacol, Res Triangle Pk, NC 27709 USA

[2] Glaxo Wellcome SpA, Med Res Ctr, Verona, Italy

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 07期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/AAC.44.7.1974-1976.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

in a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.

引用

收藏

页码：1974 / 1976

页数：3

相关论文

共 17 条

[1] Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum [J].

Allen, GD ;

Brookes, ST ;

Barrow, A ;

Dunn, JA ;

Grosse, CM .

JOURNAL OF CHROMATOGRAPHY B, 1999, 732 (02) :383-393

[2] Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies [J].

Barnett, JM ;

Cadman, A ;

Gor, D ;

Dempsey, M ;

Walters, M ;

Candlin, A ;

Tisdale, M ;

Morley, PJ ;

Owens, IJ ;

Fenton, RJ ;

Lewis, AP ;

Claas, ECJ ;

Rimmelzwaan, GF ;

De Groot, R ;

Osterhaus, ADME .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :78-87

[3]

BETTS RF, 1995, PRINCIPLES PRACTICE, P1546

[4] New approaches to influenza chemotherapy - Neuraminidase inhibitors [J].

Calfee, DP ;

Hayden, FG .

DRUGS, 1998, 56 (04) :537-553

[5] Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers [J].

Cass, LMR ;

Brown, J ;

Pickford, M ;

Fayinka, S ;

Newman, SP ;

Johansson, CJ ;

Bye, A .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :21-31

[6] Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers [J].

Cass, LMR ;

Efthymiopoulos, C ;

Bye, A .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :1-11

[7] Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables [J].

Drusano, GL ;

Bilello, JA ;

Stein, DS ;

Nessly, M ;

Meibohm, A ;

Emini, EA ;

Deutsch, P ;

Condra, J ;

Chodakewitz, J ;

Holder, DJ .

JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :360-367

[8] Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections [J].

Hayden, FG ;

Osterhaus, ADME ;

Treanor, JJ ;

Fleming, DM ;

Aoki, FY ;

Nicholson, KG ;

Bohnen, AM ;

Hirst, HM ;

Keene, O ;

Wightman, K .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :874-880

[9] Influenza virus resistance to neuraminidase inhibitors [J].

Mendel, DB ;

Sidwell, RW .

DRUG RESISTANCE UPDATES, 1998, 1 (03) :184-189

[10] Zanamivir in the prevention of influenza among healthy adults - a randomized controlled trial [J].

Monto, AS ;

Robinson, DP ;

Herlocher, ML ;

Hinson, JM ;

Elliott, MJ ;

Crisp, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (01) :31-35